Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $6.6 million.

  • Cytosorbents' Accumulated Expenses rose 1894.6% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year increase of 1894.6%. This contributed to the annual value of $6.0 million for FY2024, which is 1804.11% down from last year.
  • As of Q3 2025, Cytosorbents' Accumulated Expenses stood at $6.6 million, which was up 1894.6% from $6.0 million recorded in Q2 2025.
  • Over the past 5 years, Cytosorbents' Accumulated Expenses peaked at $10.3 million during Q4 2021, and registered a low of $5.5 million during Q3 2024.
  • Moreover, its 5-year median value for Accumulated Expenses was $7.4 million (2023), whereas its average is $7.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 4984.78% in 2021, then crashed by 3218.34% in 2023.
  • Quarter analysis of 5 years shows Cytosorbents' Accumulated Expenses stood at $10.3 million in 2021, then fell by 22.92% to $8.0 million in 2022, then dropped by 7.43% to $7.4 million in 2023, then dropped by 18.04% to $6.0 million in 2024, then rose by 8.74% to $6.6 million in 2025.
  • Its Accumulated Expenses was $6.6 million in Q3 2025, compared to $6.0 million in Q2 2025 and $5.9 million in Q1 2025.